Enhancing Antifungal Drug Discovery Through Co-Culture with Antarctic <i>Streptomyces albidoflavus</i> Strain CBMAI 1855.

ABSTRACT: Fungal infections pose a growing public health threat, creating an urgent clinical need for new antifungals. Natural products (NPs) from organisms in extreme environments are a promising source for novel drugs. Streptomyces albidoflavus CBMAI 1855 exhibited significant potential in this regard. This study aimed to (1) assess the antifungal spectrum of the CBMAI 1855 extract against key human pathogens, (2) elicit NP production through co-cultivation with fungi, correlating the metabolites with the biosynthetic gene clusters (BGCs), and (3) perform in silico toxicity predictions of the identified compounds to analyze their suitability for drug development. The crude extract of CBMAI 1855 exhibited broad-spectrum antifungal activity. The metabolomic analysis identified antifungal NPs

SUBMITTER: Giordano ALPL 

PROVIDER: S-EPMC11641416 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature